Key Takeaways for Pfizer Stock as of August 2026
- Lyme Validation: The European Medicines Agency validated the marketing application for Pfizer and partner Valneva’s Lyme disease vaccine candidate PF-07307405 on August 14, starting the formal EU review with a possible US filing later this year.
- Street Split: Pfizer stock carries 8 buys, 2 outperforms, 16 holds, 1 underperform, and 1 sell among 26 analysts, with a $29 mean target sitting 7% above the $27 close.
- Model Gap: TIKR pegs Pfizer stock at $29 by 2030, a 9% return.
- Insider Buying: CEO Albert Bourla bought $1.0M of stock at $26.34 in mid-August while director Mortimer Buckley added $960K at $25.52 days earlier, two of the largest insider purchases logged this year.
Pfizer Stock’s Lyme Vaccine Just Cleared Its First EU Hurdle
Pfizer (PFE) stock’s Lyme disease vaccine program took a real step forward on August 14, when the European Medicines Agency validated the marketing authorization application for candidate PF-07307405, developed with French vaccine maker Valneva. Validation starts the formal EU review clock. It doesn’t guarantee approval, but it confirms the dossier is complete enough for regulators to evaluate.
The filing rests on Phase 3 VALOR data showing more than 70% efficacy in people aged five and older, with no safety concerns identified. Valneva shares jumped 15.6% on the news, its best single-day move since August 2025. Kempen analysts called the Lyme program “the key” driver of the investment case and flagged a possible US filing from Pfizer in the second half of 2026, with a US approval decision potentially landing in the second half of 2027.
Pfizer’s own commentary has been building toward this. On the August 4 Q2 earnings call, Chief Scientific Officer Chris Boshoff laid out the pace of catalysts still ahead: “Here, we provide visibility into the steady cadence of milestones expected over the next 12 months, including 5 regulatory decisions, 8 key readouts and 19 pivotal study starts.” The Lyme validation is the first of those regulatory decisions to actually land, and it arrived just ten days after the call closed.
None of that shows up yet in Pfizer stock’s price. The validation is a process milestone, not a revenue event, and the market has treated it that way. But it confirms one more piece of the pipeline the Street has been reluctant to price in.
Pfizer’s Top Executives Are Buying Into the Rebound
The regulatory news landed alongside a cluster of insider purchases that reinforce the same signal. CEO Albert Bourla bought 38,000 shares at $26.34 on August 11, a $1,000,920 purchase that lifted his direct holding to 429,173 shares. Days earlier, on August 5, director Mortimer Buckley bought 37,632 shares at $25.52, worth $960,369, establishing a new position.
Two of Pfizer’s most senior insiders committing over $1.9 million combined, at prices close to where the stock trades now, is a different kind of vote than an analyst note. It says leadership sees more value in the stock than the flat consensus target below suggests.
Why Pfizer Stock’s Street Target Hasn’t Moved in a Year
Pfizer stock’s 26 covering analysts split 8 buys, 2 outperforms, 16 holds, 1 underperform, and 1 sell as of August 14. The mean target sits at $29 against a $27 close, a 7% gap that ranks among the thinnest premiums the Street has assigned Pfizer stock in the past 14 months.
That thinness is the story. Back in June 2025, the mean target stood at $29 against a $24 close, a 21% implied upside. Every quarter since, the target has barely budged, drifting between $28.58 and $29.24 while the stock price has done the moving, falling to $24 last June before climbing back to $27 now.
Coverage has widened slightly, from 23 estimates to 26, and one analyst added an underperform rating in March that has stuck since. Analysts aren’t raising targets into strength. They’re watching the price catch up to where targets already sat, and the Lyme vaccine milestone hasn’t yet moved that number either.
TIKR Values Pfizer Stock at $29, a Modest 9% Return
TIKR’s mid-case model values Pfizer at $29 by December 2030, implying a 9% total return from the current price of $27, or 2% annualized over 4.4 years.
That pace trails what large-cap pharma investors typically look for, positioning Pfizer stock as a name priced for stability through a patent-loss stretch rather than for near-term growth.
The model’s restraint tracks with what Section 2 shows: the Street hasn’t repriced Pfizer stock higher even as the price recovered, and TIKR’s own target sits in the same narrow band the mean target has occupied for over a year. The Lyme vaccine’s earliest plausible US approval falls in the second half of 2027, well outside near-term forecasts, so neither the model nor the Street is yet crediting the program with material revenue. Both are waiting for the EMA review, and a prospective US filing, to convert from process into an approved product.
Should You Invest in Pfizer Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Pfizer Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Pfizer Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze PFE stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
